John Imig
Concepts (558)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epoxide Hydrolases | 46 | 2025 | 50 | 10.890 |
Why?
| | Hypertension | 68 | 2025 | 565 | 10.360 |
Why?
| | Kidney | 64 | 2025 | 708 | 8.490 |
Why?
| | Kidney Diseases | 23 | 2025 | 220 | 7.730 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 20 | 2025 | 20 | 4.830 |
Why?
| | Blood Pressure | 56 | 2021 | 534 | 4.460 |
Why?
| | Cytochrome P-450 Enzyme System | 27 | 2020 | 191 | 4.450 |
Why?
| | Ureteral Obstruction | 7 | 2025 | 62 | 4.020 |
Why?
| | Eicosanoids | 15 | 2022 | 17 | 3.850 |
Why?
| | Vasodilation | 26 | 2020 | 99 | 3.710 |
Why?
| | Animals | 147 | 2025 | 13523 | 3.320 |
Why?
| | Rats | 92 | 2025 | 3202 | 3.250 |
Why?
| | Renal Insufficiency, Chronic | 9 | 2024 | 187 | 3.130 |
Why?
| | Antihypertensive Agents | 21 | 2024 | 131 | 3.010 |
Why?
| | Enzyme Inhibitors | 21 | 2025 | 374 | 2.880 |
Why?
| | Hydroxyeicosatetraenoic Acids | 15 | 2020 | 19 | 2.570 |
Why?
| | Cardiovascular Diseases | 9 | 2023 | 486 | 2.490 |
Why?
| | Angiotensin II | 32 | 2019 | 162 | 2.470 |
Why?
| | Diabetic Nephropathies | 9 | 2021 | 61 | 2.390 |
Why?
| | Endothelium, Vascular | 13 | 2016 | 261 | 2.390 |
Why?
| | Kidney Glomerulus | 9 | 2025 | 41 | 2.290 |
Why?
| | Arachidonic Acids | 9 | 2019 | 22 | 2.120 |
Why?
| | Nephritis | 7 | 2025 | 23 | 2.110 |
Why?
| | Diabetes Mellitus, Experimental | 8 | 2021 | 137 | 2.080 |
Why?
| | Sodium Chloride, Dietary | 11 | 2023 | 35 | 1.880 |
Why?
| | Obesity | 13 | 2018 | 1162 | 1.830 |
Why?
| | Cyclooxygenase 2 | 6 | 2025 | 50 | 1.720 |
Why?
| | Disease Models, Animal | 26 | 2025 | 1484 | 1.720 |
Why?
| | PPAR gamma | 4 | 2020 | 73 | 1.690 |
Why?
| | Fibrosis | 11 | 2025 | 197 | 1.660 |
Why?
| | Rats, Sprague-Dawley | 47 | 2018 | 1552 | 1.620 |
Why?
| | Oxidative Stress | 15 | 2024 | 810 | 1.590 |
Why?
| | Epoxy Compounds | 5 | 2021 | 47 | 1.570 |
Why?
| | Renal Circulation | 14 | 2025 | 56 | 1.560 |
Why?
| | Cyclooxygenase 2 Inhibitors | 3 | 2025 | 22 | 1.540 |
Why?
| | Male | 101 | 2025 | 26696 | 1.530 |
Why?
| | Mice | 37 | 2025 | 5965 | 1.440 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2021 | 561 | 1.430 |
Why?
| | Arterioles | 15 | 2025 | 32 | 1.400 |
Why?
| | Inflammation | 14 | 2024 | 642 | 1.400 |
Why?
| | Lauric Acids | 5 | 2009 | 8 | 1.380 |
Why?
| | Mesenteric Arteries | 9 | 2017 | 41 | 1.350 |
Why?
| | Adamantane | 5 | 2009 | 24 | 1.350 |
Why?
| | Fatty Acids | 3 | 2023 | 151 | 1.340 |
Why?
| | Vasodilator Agents | 9 | 2018 | 93 | 1.300 |
Why?
| | Blood Glucose | 9 | 2021 | 471 | 1.300 |
Why?
| | Benzimidazoles | 6 | 2014 | 50 | 1.290 |
Why?
| | Sodium Chloride | 6 | 2020 | 56 | 1.210 |
Why?
| | Phenylurea Compounds | 3 | 2025 | 18 | 1.190 |
Why?
| | Myocardial Infarction | 5 | 2021 | 413 | 1.170 |
Why?
| | Albuminuria | 13 | 2025 | 49 | 1.140 |
Why?
| | Rats, Inbred SHR | 11 | 2020 | 42 | 1.060 |
Why?
| | Hypertension, Renal | 7 | 2025 | 21 | 1.060 |
Why?
| | Glomerulosclerosis, Focal Segmental | 2 | 2025 | 15 | 0.990 |
Why?
| | Acute Kidney Injury | 5 | 2022 | 315 | 0.960 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2025 | 29 | 0.960 |
Why?
| | Myocardium | 5 | 2021 | 480 | 0.940 |
Why?
| | Oxadiazoles | 3 | 2014 | 9 | 0.930 |
Why?
| | Arachidonic Acid | 12 | 2020 | 34 | 0.910 |
Why?
| | Mice, Inbred C57BL | 17 | 2025 | 1903 | 0.900 |
Why?
| | Benzoates | 8 | 2014 | 21 | 0.890 |
Why?
| | Collagen | 5 | 2024 | 212 | 0.830 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 230 | 0.820 |
Why?
| | Phosphates | 1 | 2022 | 50 | 0.790 |
Why?
| | Rats, Transgenic | 16 | 2024 | 21 | 0.790 |
Why?
| | Public Health | 1 | 2024 | 221 | 0.770 |
Why?
| | Vasoconstriction | 13 | 2025 | 56 | 0.760 |
Why?
| | Solubility | 6 | 2025 | 80 | 0.760 |
Why?
| | Humans | 44 | 2025 | 52336 | 0.760 |
Why?
| | Membrane Proteins | 4 | 2025 | 340 | 0.750 |
Why?
| | Dietary Fats | 4 | 2011 | 130 | 0.740 |
Why?
| | Bradykinin | 3 | 2015 | 17 | 0.740 |
Why?
| | Virus Diseases | 1 | 2022 | 45 | 0.730 |
Why?
| | Hydroxyproline | 2 | 2024 | 19 | 0.730 |
Why?
| | Rats, Inbred WKY | 8 | 2021 | 34 | 0.720 |
Why?
| | Metabolic Diseases | 1 | 2021 | 47 | 0.700 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2018 | 53 | 0.690 |
Why?
| | Water-Electrolyte Balance | 1 | 2020 | 19 | 0.680 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 5 | 2016 | 25 | 0.680 |
Why?
| | Blood Vessels | 1 | 2020 | 71 | 0.670 |
Why?
| | Muscle, Smooth, Vascular | 9 | 2021 | 137 | 0.670 |
Why?
| | Renin-Angiotensin System | 9 | 2019 | 56 | 0.670 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 122 | 0.650 |
Why?
| | Rats, Zucker | 8 | 2018 | 73 | 0.630 |
Why?
| | Urea | 7 | 2014 | 82 | 0.630 |
Why?
| | Kidney Transplantation | 1 | 2021 | 192 | 0.620 |
Why?
| | Liver Cirrhosis | 2 | 2018 | 241 | 0.620 |
Why?
| | Heart Diseases | 1 | 2021 | 222 | 0.610 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2016 | 29 | 0.600 |
Why?
| | Nitric Oxide | 5 | 2016 | 244 | 0.600 |
Why?
| | Insulin Resistance | 6 | 2018 | 277 | 0.600 |
Why?
| | Proteinuria | 3 | 2016 | 39 | 0.600 |
Why?
| | Isoenzymes | 5 | 2006 | 167 | 0.590 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 62 | 0.580 |
Why?
| | Ventricular Remodeling | 1 | 2018 | 65 | 0.570 |
Why?
| | Renin | 7 | 2016 | 18 | 0.570 |
Why?
| | Drug Discovery | 1 | 2018 | 93 | 0.550 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 4 | 2018 | 44 | 0.540 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 172 | 0.540 |
Why?
| | Neuroprotective Agents | 2 | 2009 | 101 | 0.520 |
Why?
| | Natriuresis | 4 | 2020 | 6 | 0.520 |
Why?
| | Kidney Failure, Chronic | 2 | 2009 | 210 | 0.520 |
Why?
| | Superoxides | 2 | 2016 | 46 | 0.520 |
Why?
| | Microcirculation | 11 | 2016 | 63 | 0.510 |
Why?
| | Cisplatin | 2 | 2021 | 285 | 0.510 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 39 | 0.510 |
Why?
| | Arachidonate Lipoxygenases | 1 | 2015 | 1 | 0.500 |
Why?
| | Brain Ischemia | 2 | 2009 | 161 | 0.500 |
Why?
| | Aminopeptidases | 1 | 2015 | 15 | 0.500 |
Why?
| | Sodium | 6 | 2023 | 94 | 0.490 |
Why?
| | Cerebral Arteries | 1 | 2015 | 30 | 0.480 |
Why?
| | Rats, Inbred Dahl | 7 | 2025 | 11 | 0.480 |
Why?
| | Metabolome | 1 | 2016 | 102 | 0.480 |
Why?
| | Macrophages | 7 | 2021 | 378 | 0.470 |
Why?
| | Angiotensins | 3 | 2010 | 12 | 0.470 |
Why?
| | Signal Transduction | 11 | 2018 | 1716 | 0.470 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 236 | 0.460 |
Why?
| | Sodium Channel Blockers | 1 | 2014 | 14 | 0.460 |
Why?
| | Tetrazoles | 5 | 2014 | 41 | 0.460 |
Why?
| | Gene Expression | 3 | 2015 | 623 | 0.450 |
Why?
| | Cardiomegaly | 3 | 2021 | 57 | 0.450 |
Why?
| | Protective Agents | 1 | 2014 | 17 | 0.450 |
Why?
| | Lipids | 5 | 2023 | 157 | 0.450 |
Why?
| | Endothelial Cells | 2 | 2013 | 283 | 0.440 |
Why?
| | Hypertension, Renovascular | 4 | 2016 | 12 | 0.440 |
Why?
| | Homeostasis | 5 | 2016 | 206 | 0.430 |
Why?
| | Kidney Tubules, Proximal | 4 | 2013 | 61 | 0.420 |
Why?
| | Captopril | 2 | 2016 | 13 | 0.420 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 3 | 2013 | 12 | 0.410 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2010 | 397 | 0.410 |
Why?
| | Acetylcholine | 5 | 2016 | 55 | 0.410 |
Why?
| | Calcium | 5 | 2021 | 375 | 0.410 |
Why?
| | Cyclooxygenase Inhibitors | 3 | 2016 | 39 | 0.400 |
Why?
| | Cerebrovascular Circulation | 2 | 2011 | 128 | 0.400 |
Why?
| | Enalapril | 3 | 2021 | 15 | 0.400 |
Why?
| | Cyclic N-Oxides | 2 | 2009 | 12 | 0.390 |
Why?
| | Benzenesulfonates | 1 | 2012 | 10 | 0.390 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 78 | 0.390 |
Why?
| | Thiazolidinediones | 1 | 2012 | 84 | 0.390 |
Why?
| | Growth Inhibitors | 1 | 2012 | 26 | 0.390 |
Why?
| | Apoptosis | 8 | 2019 | 1127 | 0.380 |
Why?
| | Vasoconstrictor Agents | 7 | 2019 | 81 | 0.380 |
Why?
| | Immunologic Factors | 1 | 2013 | 117 | 0.380 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2012 | 186 | 0.380 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2012 | 13 | 0.380 |
Why?
| | Hypertension, Malignant | 3 | 2018 | 4 | 0.380 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1206 | 0.370 |
Why?
| | Heart Failure | 3 | 2024 | 571 | 0.370 |
Why?
| | Sulfones | 3 | 2010 | 24 | 0.370 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2019 | 1377 | 0.370 |
Why?
| | Pyridines | 2 | 2012 | 133 | 0.370 |
Why?
| | Endoplasmic Reticulum Stress | 4 | 2017 | 50 | 0.360 |
Why?
| | Chemokine CCL2 | 7 | 2011 | 69 | 0.360 |
Why?
| | NG-Nitroarginine Methyl Ester | 3 | 2016 | 12 | 0.360 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 210 | 0.360 |
Why?
| | Potassium Channels | 3 | 2012 | 32 | 0.350 |
Why?
| | Valine | 1 | 2011 | 57 | 0.350 |
Why?
| | Drug Delivery Systems | 2 | 2009 | 146 | 0.350 |
Why?
| | Arrhythmias, Cardiac | 3 | 2021 | 97 | 0.340 |
Why?
| | Actins | 2 | 2024 | 117 | 0.330 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2009 | 7 | 0.330 |
Why?
| | Simvastatin | 1 | 2009 | 29 | 0.320 |
Why?
| | Mice, Knockout | 10 | 2021 | 909 | 0.320 |
Why?
| | Oleic Acids | 1 | 2009 | 8 | 0.320 |
Why?
| | Oxidoreductases | 2 | 2008 | 59 | 0.310 |
Why?
| | Potassium, Dietary | 1 | 2009 | 2 | 0.310 |
Why?
| | Thrombosis | 2 | 2022 | 253 | 0.300 |
Why?
| | PPAR alpha | 2 | 2006 | 61 | 0.300 |
Why?
| | Gene Deletion | 2 | 2009 | 276 | 0.300 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 220 | 0.300 |
Why?
| | Cytochrome P-450 CYP1A1 | 5 | 2018 | 26 | 0.300 |
Why?
| | Hypnotics and Sedatives | 1 | 2009 | 72 | 0.300 |
Why?
| | Receptor, Angiotensin, Type 1 | 4 | 2005 | 56 | 0.300 |
Why?
| | Sulfonamides | 2 | 2022 | 133 | 0.290 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 583 | 0.290 |
Why?
| | Carrier Proteins | 2 | 2013 | 326 | 0.290 |
Why?
| | Potassium Channels, Calcium-Activated | 2 | 2007 | 5 | 0.280 |
Why?
| | Receptors, CCR2 | 1 | 2007 | 13 | 0.280 |
Why?
| | Body Weight | 4 | 2014 | 522 | 0.280 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 1006 | 0.280 |
Why?
| | Nitric Oxide Synthase | 4 | 2016 | 64 | 0.270 |
Why?
| | Hemodynamics | 3 | 2015 | 261 | 0.270 |
Why?
| | Receptors, Prostaglandin E | 2 | 2007 | 2 | 0.270 |
Why?
| | Calcium Channels | 2 | 2005 | 42 | 0.270 |
Why?
| | Drug Evaluation, Preclinical | 4 | 2018 | 143 | 0.270 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2006 | 17 | 0.260 |
Why?
| | Disease Progression | 5 | 2015 | 870 | 0.260 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 67 | 0.260 |
Why?
| | Glucose Tolerance Test | 2 | 2018 | 61 | 0.260 |
Why?
| | Immunoglobulin G | 2 | 2007 | 195 | 0.250 |
Why?
| | Cholesterol | 3 | 2014 | 156 | 0.250 |
Why?
| | Heme Oxygenase-1 | 2 | 2019 | 18 | 0.250 |
Why?
| | Fenofibrate | 1 | 2006 | 18 | 0.250 |
Why?
| | Hypolipidemic Agents | 1 | 2006 | 30 | 0.250 |
Why?
| | Purinergic P2 Receptor Agonists | 2 | 2005 | 3 | 0.240 |
Why?
| | Cerebral Infarction | 1 | 2005 | 34 | 0.240 |
Why?
| | NF-kappa B | 5 | 2013 | 328 | 0.240 |
Why?
| | Mesangial Cells | 1 | 2025 | 5 | 0.240 |
Why?
| | Insulin | 5 | 2014 | 481 | 0.240 |
Why?
| | Hyperglycemia | 2 | 2017 | 88 | 0.240 |
Why?
| | RNA, Messenger | 6 | 2007 | 1142 | 0.240 |
Why?
| | Chloride Channels | 2 | 2021 | 26 | 0.240 |
Why?
| | Adenosine Triphosphate | 3 | 2005 | 208 | 0.240 |
Why?
| | Lactones | 1 | 2004 | 25 | 0.230 |
Why?
| | Piperidines | 1 | 2025 | 97 | 0.230 |
Why?
| | Islets of Langerhans | 2 | 2017 | 26 | 0.230 |
Why?
| | Kidney Cortex | 5 | 2007 | 23 | 0.220 |
Why?
| | Nephrotic Syndrome | 1 | 2024 | 19 | 0.220 |
Why?
| | Cell Line, Tumor | 3 | 2021 | 1436 | 0.220 |
Why?
| | Heart | 2 | 2019 | 357 | 0.220 |
Why?
| | Administration, Oral | 5 | 2017 | 451 | 0.220 |
Why?
| | Biological Factors | 1 | 2004 | 12 | 0.220 |
Why?
| | Fibroblasts | 3 | 2021 | 359 | 0.220 |
Why?
| | Osteonectin | 3 | 2008 | 10 | 0.220 |
Why?
| | Time Factors | 8 | 2016 | 2957 | 0.220 |
Why?
| | Rats, Inbred Strains | 3 | 2015 | 187 | 0.220 |
Why?
| | Hypertrophy | 1 | 2024 | 54 | 0.220 |
Why?
| | Dinoprostone | 2 | 2007 | 49 | 0.220 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2003 | 2 | 0.210 |
Why?
| | Receptor, Bradykinin B2 | 1 | 2003 | 7 | 0.210 |
Why?
| | Stroke Volume | 1 | 2024 | 153 | 0.210 |
Why?
| | Female | 13 | 2025 | 28105 | 0.200 |
Why?
| | Thiobarbituric Acid Reactive Substances | 3 | 2013 | 11 | 0.200 |
Why?
| | Doxorubicin | 1 | 2024 | 239 | 0.200 |
Why?
| | Osteopontin | 1 | 2022 | 16 | 0.200 |
Why?
| | Minerals | 1 | 2022 | 26 | 0.200 |
Why?
| | Alprostadil | 1 | 2002 | 10 | 0.200 |
Why?
| | Diet, High-Fat | 3 | 2021 | 237 | 0.200 |
Why?
| | Sex Characteristics | 1 | 2024 | 198 | 0.190 |
Why?
| | Steroid 16-alpha-Hydroxylase | 4 | 2016 | 10 | 0.190 |
Why?
| | Amides | 4 | 2018 | 37 | 0.190 |
Why?
| | Carbazoles | 1 | 2022 | 18 | 0.190 |
Why?
| | Substance P | 1 | 2021 | 23 | 0.190 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 4 | 2016 | 74 | 0.190 |
Why?
| | Tachycardia, Ventricular | 1 | 2021 | 46 | 0.180 |
Why?
| | Inflammation Mediators | 3 | 2013 | 117 | 0.180 |
Why?
| | Adaptation, Physiological | 1 | 2002 | 111 | 0.180 |
Why?
| | Desoxycorticosterone | 3 | 2009 | 6 | 0.180 |
Why?
| | Isoprostanes | 1 | 2020 | 2 | 0.180 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 20 | 0.180 |
Why?
| | Paracrine Communication | 1 | 2020 | 12 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2021 | 24 | 0.170 |
Why?
| | Tumor Burden | 1 | 2021 | 136 | 0.170 |
Why?
| | Mice, Nude | 1 | 2021 | 236 | 0.170 |
Why?
| | Peptides | 2 | 2015 | 229 | 0.170 |
Why?
| | Down-Regulation | 3 | 2018 | 347 | 0.170 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 222 | 0.170 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2020 | 14 | 0.170 |
Why?
| | Potassium | 1 | 2020 | 56 | 0.170 |
Why?
| | Metabolic Networks and Pathways | 1 | 2020 | 93 | 0.170 |
Why?
| | Risk | 1 | 2021 | 313 | 0.170 |
Why?
| | Muscle Contraction | 1 | 2021 | 116 | 0.170 |
Why?
| | Renal Dialysis | 1 | 2021 | 179 | 0.160 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2019 | 10 | 0.160 |
Why?
| | Golgi Apparatus | 1 | 2021 | 101 | 0.160 |
Why?
| | Forecasting | 1 | 2020 | 154 | 0.160 |
Why?
| | Chenodeoxycholic Acid | 1 | 2019 | 7 | 0.160 |
Why?
| | Endothelin-1 | 5 | 2008 | 34 | 0.160 |
Why?
| | Cell Survival | 3 | 2025 | 602 | 0.160 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2012 | 82 | 0.160 |
Why?
| | Mast Cells | 1 | 2019 | 55 | 0.160 |
Why?
| | Cardiotonic Agents | 2 | 2012 | 84 | 0.150 |
Why?
| | Structure-Activity Relationship | 3 | 2025 | 406 | 0.150 |
Why?
| | KATP Channels | 1 | 2018 | 6 | 0.150 |
Why?
| | 3' Untranslated Regions | 1 | 2018 | 55 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2018 | 395 | 0.150 |
Why?
| | Proteolysis | 1 | 2018 | 102 | 0.140 |
Why?
| | Antioxidants | 3 | 2009 | 258 | 0.140 |
Why?
| | Weight Gain | 3 | 2010 | 240 | 0.140 |
Why?
| | Protein Phosphatase 2 | 2 | 2008 | 4 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB1 | 2 | 2009 | 123 | 0.140 |
Why?
| | Muscle Cells | 2 | 2008 | 20 | 0.140 |
Why?
| | Epithelial Sodium Channels | 2 | 2013 | 7 | 0.140 |
Why?
| | Blood Urea Nitrogen | 2 | 2016 | 42 | 0.130 |
Why?
| | Fatty Liver | 1 | 2018 | 142 | 0.130 |
Why?
| | Carcinoma | 2 | 2008 | 137 | 0.130 |
Why?
| | Vascular Resistance | 2 | 2006 | 50 | 0.130 |
Why?
| | Species Specificity | 2 | 2016 | 192 | 0.130 |
Why?
| | Indomethacin | 1 | 2016 | 35 | 0.130 |
Why?
| | Podocytes | 2 | 2017 | 18 | 0.130 |
Why?
| | Stereoisomerism | 1 | 2016 | 101 | 0.130 |
Why?
| | Cyclosporine | 1 | 2016 | 67 | 0.130 |
Why?
| | Renal Artery | 1 | 2016 | 32 | 0.120 |
Why?
| | Receptor, Adenosine A2B | 1 | 2015 | 3 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2016 | 58 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 468 | 0.120 |
Why?
| | Whole-Body Irradiation | 1 | 2016 | 127 | 0.120 |
Why?
| | Phosphorylation | 3 | 2013 | 531 | 0.120 |
Why?
| | Ion Channel Gating | 2 | 2006 | 33 | 0.120 |
Why?
| | Radiation-Protective Agents | 1 | 2016 | 72 | 0.120 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 81 | 0.120 |
Why?
| | Cytokines | 3 | 2021 | 625 | 0.120 |
Why?
| | Nephrosclerosis | 1 | 2014 | 4 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 407 | 0.120 |
Why?
| | Glucose | 2 | 2021 | 357 | 0.120 |
Why?
| | Receptors, Purinergic P2 | 2 | 2005 | 26 | 0.110 |
Why?
| | Calcium Signaling | 2 | 2005 | 52 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2014 | 43 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2016 | 243 | 0.110 |
Why?
| | Glucose Intolerance | 1 | 2014 | 27 | 0.110 |
Why?
| | Fructose | 1 | 2013 | 22 | 0.110 |
Why?
| | Cell Death | 3 | 2025 | 176 | 0.110 |
Why?
| | Caspase Inhibitors | 1 | 2013 | 16 | 0.110 |
Why?
| | Coronary Vessels | 2 | 2014 | 169 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2005 | 181 | 0.110 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2021 | 95 | 0.110 |
Why?
| | Ovarian Neoplasms | 2 | 2008 | 459 | 0.110 |
Why?
| | Eye Diseases | 1 | 2013 | 29 | 0.110 |
Why?
| | Triglycerides | 1 | 2014 | 165 | 0.100 |
Why?
| | Receptor, Endothelin A | 2 | 2019 | 8 | 0.100 |
Why?
| | Cross-Linking Reagents | 1 | 2013 | 44 | 0.100 |
Why?
| | Retina | 1 | 2013 | 63 | 0.100 |
Why?
| | Rats, Wistar | 2 | 2013 | 194 | 0.100 |
Why?
| | Nephrectomy | 3 | 2019 | 82 | 0.100 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2013 | 102 | 0.100 |
Why?
| | Creatinine | 1 | 2013 | 149 | 0.100 |
Why?
| | Inflammasomes | 1 | 2013 | 66 | 0.100 |
Why?
| | Indoles | 4 | 2018 | 278 | 0.100 |
Why?
| | Cyclic AMP | 2 | 2015 | 91 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 120 | 0.100 |
Why?
| | Spin Labels | 2 | 2009 | 6 | 0.100 |
Why?
| | Interleukin-6 | 3 | 2015 | 278 | 0.100 |
Why?
| | Angiotensin I | 3 | 2016 | 14 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2013 | 232 | 0.100 |
Why?
| | Small Molecule Libraries | 1 | 2013 | 67 | 0.100 |
Why?
| | HeLa Cells | 1 | 2013 | 263 | 0.100 |
Why?
| | Niacinamide | 1 | 2012 | 24 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 129 | 0.100 |
Why?
| | Receptors, Angiotensin | 2 | 2002 | 11 | 0.100 |
Why?
| | Blotting, Western | 4 | 2010 | 596 | 0.100 |
Why?
| | Immunity, Innate | 1 | 2013 | 117 | 0.090 |
Why?
| | Syndrome | 1 | 2012 | 247 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 166 | 0.090 |
Why?
| | Platelet Aggregation | 1 | 2012 | 70 | 0.090 |
Why?
| | Transcription Factor RelA | 1 | 2011 | 32 | 0.090 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2011 | 7 | 0.090 |
Why?
| | Catalase | 1 | 2011 | 74 | 0.090 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 86 | 0.090 |
Why?
| | Cell Adhesion Molecules | 1 | 2011 | 87 | 0.090 |
Why?
| | Receptors, Purinergic P2X | 3 | 2005 | 5 | 0.090 |
Why?
| | Pyrrolidines | 3 | 2005 | 69 | 0.090 |
Why?
| | Models, Biological | 2 | 2021 | 743 | 0.090 |
Why?
| | Hydralazine | 2 | 2014 | 3 | 0.080 |
Why?
| | Reserpine | 2 | 2014 | 13 | 0.080 |
Why?
| | Hydrochlorothiazide | 2 | 2014 | 8 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2011 | 1589 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2010 | 54 | 0.080 |
Why?
| | Nitrites | 1 | 2010 | 31 | 0.080 |
Why?
| | Biphenyl Compounds | 3 | 2005 | 31 | 0.080 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 47 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2011 | 215 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor | 2 | 2007 | 39 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 464 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2010 | 134 | 0.080 |
Why?
| | TRPV Cation Channels | 1 | 2009 | 8 | 0.080 |
Why?
| | Cardiovascular Agents | 1 | 2009 | 60 | 0.080 |
Why?
| | Microvessels | 1 | 2009 | 32 | 0.080 |
Why?
| | Receptors, Cannabinoid | 1 | 2009 | 18 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 2 | 2007 | 58 | 0.080 |
Why?
| | Mice, Obese | 1 | 2009 | 22 | 0.080 |
Why?
| | Endothelins | 2 | 2005 | 16 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 252 | 0.080 |
Why?
| | Aorta | 2 | 2007 | 169 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 145 | 0.070 |
Why?
| | Receptors, CCR1 | 1 | 2007 | 10 | 0.070 |
Why?
| | Cattle | 3 | 2014 | 207 | 0.070 |
Why?
| | Ascitic Fluid | 1 | 2007 | 13 | 0.070 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2008 | 57 | 0.070 |
Why?
| | Cell Separation | 2 | 2005 | 74 | 0.070 |
Why?
| | Capillaries | 2 | 2005 | 49 | 0.070 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2007 | 62 | 0.070 |
Why?
| | Glomerular Filtration Rate | 3 | 2013 | 124 | 0.070 |
Why?
| | Oxygenases | 2 | 2007 | 16 | 0.070 |
Why?
| | Norepinephrine | 2 | 2010 | 112 | 0.070 |
Why?
| | Charybdotoxin | 1 | 2006 | 1 | 0.070 |
Why?
| | Okadaic Acid | 1 | 2006 | 7 | 0.070 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2006 | 6 | 0.070 |
Why?
| | Adult | 1 | 2023 | 14139 | 0.070 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2004 | 20 | 0.070 |
Why?
| | Tetraethylammonium Compounds | 1 | 2006 | 3 | 0.070 |
Why?
| | Triazoles | 1 | 2007 | 115 | 0.060 |
Why?
| | Leptin | 1 | 2007 | 148 | 0.060 |
Why?
| | Arteries | 1 | 2007 | 94 | 0.060 |
Why?
| | Peritoneal Neoplasms | 1 | 2007 | 65 | 0.060 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 1 | 2006 | 14 | 0.060 |
Why?
| | Receptor, Endothelin B | 1 | 2005 | 3 | 0.060 |
Why?
| | Penile Erection | 1 | 2006 | 24 | 0.060 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 60 | 0.060 |
Why?
| | Immunoblotting | 1 | 2006 | 119 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 144 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 87 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2005 | 128 | 0.060 |
Why?
| | Penis | 1 | 2006 | 84 | 0.060 |
Why?
| | Juxtaglomerular Apparatus | 1 | 2004 | 2 | 0.060 |
Why?
| | Nephrons | 1 | 2004 | 6 | 0.060 |
Why?
| | Molecular Structure | 1 | 2006 | 315 | 0.060 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 2 | 2014 | 16 | 0.060 |
Why?
| | Thromboxane B2 | 1 | 2004 | 4 | 0.060 |
Why?
| | Chemokines | 1 | 2004 | 79 | 0.060 |
Why?
| | Spectrometry, Fluorescence | 1 | 2004 | 46 | 0.060 |
Why?
| | Linoleic Acid | 1 | 2004 | 16 | 0.060 |
Why?
| | Calcium Channels, L-Type | 1 | 2004 | 69 | 0.060 |
Why?
| | Suramin | 1 | 2003 | 10 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2024 | 78 | 0.050 |
Why?
| | Lipoxygenase | 1 | 2003 | 1 | 0.050 |
Why?
| | Dogs | 1 | 2004 | 183 | 0.050 |
Why?
| | Survival Rate | 2 | 2018 | 940 | 0.050 |
Why?
| | Prostaglandins E, Synthetic | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Prostaglandin E, EP2 Subtype | 1 | 2002 | 1 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2007 | 1110 | 0.050 |
Why?
| | Heart Rate | 1 | 2004 | 319 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2006 | 315 | 0.050 |
Why?
| | Chemoprevention | 1 | 2022 | 19 | 0.050 |
Why?
| | Endosomes | 1 | 2002 | 36 | 0.050 |
Why?
| | Up-Regulation | 1 | 2003 | 462 | 0.050 |
Why?
| | Biological Transport | 2 | 2013 | 158 | 0.050 |
Why?
| | Promoter Regions, Genetic | 2 | 2016 | 474 | 0.050 |
Why?
| | Peptide Fragments | 2 | 2016 | 203 | 0.040 |
Why?
| | Receptors, Leptin | 1 | 2021 | 52 | 0.040 |
Why?
| | Regional Blood Flow | 2 | 2011 | 109 | 0.040 |
Why?
| | Risk Factors | 1 | 2009 | 3872 | 0.040 |
Why?
| | Sodium, Dietary | 1 | 2021 | 24 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2011 | 5407 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 2014 | 195 | 0.040 |
Why?
| | Random Allocation | 2 | 2013 | 287 | 0.040 |
Why?
| | Arterio-Arterial Fistula | 1 | 2019 | 2 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2019 | 58 | 0.040 |
Why?
| | Aging | 1 | 2004 | 708 | 0.040 |
Why?
| | Pinacidil | 1 | 2018 | 1 | 0.040 |
Why?
| | Phenotype | 1 | 2021 | 799 | 0.040 |
Why?
| | Pulmonary Artery | 1 | 2019 | 146 | 0.040 |
Why?
| | Base Sequence | 2 | 2010 | 648 | 0.040 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2017 | 11 | 0.040 |
Why?
| | Mice, Mutant Strains | 2 | 2007 | 71 | 0.040 |
Why?
| | Dinoprost | 2 | 2007 | 7 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2010 | 563 | 0.030 |
Why?
| | Rats, Inbred BN | 1 | 2016 | 13 | 0.030 |
Why?
| | Albumins | 1 | 2016 | 32 | 0.030 |
Why?
| | Hydrogen Peroxide | 2 | 2007 | 120 | 0.030 |
Why?
| | Fas Ligand Protein | 1 | 2016 | 17 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 33 | 0.030 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2015 | 5 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2015 | 21 | 0.030 |
Why?
| | Aminopyridines | 1 | 2015 | 15 | 0.030 |
Why?
| | Autophagy | 1 | 2017 | 197 | 0.030 |
Why?
| | Telemetry | 1 | 2015 | 29 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 34 | 0.030 |
Why?
| | Oxamic Acid | 1 | 2014 | 1 | 0.030 |
Why?
| | Glomerular Basement Membrane | 1 | 2014 | 10 | 0.030 |
Why?
| | Chemistry Techniques, Synthetic | 1 | 2014 | 21 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 172 | 0.030 |
Why?
| | Pressure | 2 | 2006 | 103 | 0.030 |
Why?
| | Orchiectomy | 1 | 2014 | 38 | 0.030 |
Why?
| | Molecular Mimicry | 1 | 2014 | 36 | 0.030 |
Why?
| | Necrosis | 1 | 2014 | 173 | 0.030 |
Why?
| | Sex Factors | 2 | 2008 | 727 | 0.030 |
Why?
| | Sweetening Agents | 1 | 2013 | 22 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 49 | 0.030 |
Why?
| | Cell Proliferation | 2 | 2008 | 1029 | 0.030 |
Why?
| | Epithelial Sodium Channel Blockers | 1 | 2013 | 2 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 179 | 0.030 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2013 | 27 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 97 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2013 | 165 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 173 | 0.020 |
Why?
| | Muscle Relaxation | 1 | 2012 | 15 | 0.020 |
Why?
| | Isometric Contraction | 1 | 2012 | 21 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2012 | 57 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2012 | 111 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2012 | 109 | 0.020 |
Why?
| | Amitrole | 1 | 2011 | 1 | 0.020 |
Why?
| | Drug Contamination | 1 | 2011 | 4 | 0.020 |
Why?
| | Losartan | 1 | 2011 | 27 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2011 | 11 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 636 | 0.020 |
Why?
| | Amidines | 1 | 2011 | 6 | 0.020 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 18 | 0.020 |
Why?
| | Renal Plasma Flow | 1 | 2011 | 4 | 0.020 |
Why?
| | Pancreas | 1 | 2011 | 71 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 293 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 69 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 209 | 0.020 |
Why?
| | Mutation | 1 | 2015 | 1351 | 0.020 |
Why?
| | Androgens | 1 | 2009 | 70 | 0.020 |
Why?
| | U937 Cells | 1 | 2008 | 15 | 0.020 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 13 | 0.020 |
Why?
| | Luteinizing Hormone | 1 | 2008 | 50 | 0.020 |
Why?
| | Epithelium | 1 | 2008 | 65 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2008 | 19 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 1 | 2008 | 40 | 0.020 |
Why?
| | Estrogen Replacement Therapy | 1 | 2008 | 28 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2008 | 145 | 0.020 |
Why?
| | Cricetulus | 1 | 2008 | 104 | 0.020 |
Why?
| | Organ Specificity | 1 | 2008 | 117 | 0.020 |
Why?
| | CHO Cells | 1 | 2008 | 125 | 0.020 |
Why?
| | Cricetinae | 1 | 2008 | 194 | 0.020 |
Why?
| | Ovary | 1 | 2008 | 107 | 0.020 |
Why?
| | Mineralocorticoids | 1 | 2007 | 2 | 0.020 |
Why?
| | Testosterone | 1 | 2008 | 141 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2007 | 11 | 0.020 |
Why?
| | Receptors, Prostaglandin E, EP1 Subtype | 1 | 2007 | 1 | 0.020 |
Why?
| | Glomerular Mesangium | 1 | 2007 | 7 | 0.020 |
Why?
| | Integrins | 1 | 2007 | 32 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2008 | 278 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2007 | 52 | 0.020 |
Why?
| | Cobalt | 1 | 2007 | 17 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2007 | 70 | 0.020 |
Why?
| | Metalloendopeptidases | 1 | 2007 | 70 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 985 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2007 | 16 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2007 | 164 | 0.020 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 62 | 0.020 |
Why?
| | Heterozygote | 1 | 2007 | 91 | 0.020 |
Why?
| | Estradiol | 1 | 2008 | 215 | 0.020 |
Why?
| | Receptors, Bradykinin | 1 | 2006 | 2 | 0.020 |
Why?
| | Drug Combinations | 1 | 2007 | 134 | 0.020 |
Why?
| | Drug Synergism | 1 | 2006 | 148 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2006 | 18 | 0.020 |
Why?
| | Viper Venoms | 1 | 2005 | 7 | 0.020 |
Why?
| | Microsomes | 1 | 2006 | 35 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2006 | 77 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2006 | 107 | 0.020 |
Why?
| | Receptor, Adenosine A1 | 1 | 2005 | 1 | 0.020 |
Why?
| | Uridine Triphosphate | 1 | 2005 | 10 | 0.020 |
Why?
| | Fibronectins | 1 | 2005 | 37 | 0.020 |
Why?
| | Intracellular Membranes | 1 | 2005 | 22 | 0.020 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| | Gallic Acid | 1 | 2005 | 2 | 0.020 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2005 | 8 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2006 | 272 | 0.020 |
Why?
| | Clofibrate | 1 | 2005 | 7 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2005 | 19 | 0.020 |
Why?
| | Diltiazem | 1 | 2005 | 10 | 0.020 |
Why?
| | ortho-Aminobenzoates | 1 | 2005 | 6 | 0.020 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 138 | 0.010 |
Why?
| | Calibration | 1 | 2005 | 57 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2007 | 425 | 0.010 |
Why?
| | Adenosine | 1 | 2005 | 72 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2005 | 60 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 372 | 0.010 |
Why?
| | Xanthines | 1 | 2003 | 8 | 0.010 |
Why?
| | Chronic Disease | 1 | 2006 | 583 | 0.010 |
Why?
| | Furosemide | 1 | 2003 | 13 | 0.010 |
Why?
| | Diuretics | 1 | 2003 | 31 | 0.010 |
Why?
| | Perfusion | 1 | 2003 | 48 | 0.010 |
Why?
| | Mixed Function Oxygenases | 1 | 2003 | 25 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2005 | 1021 | 0.010 |
Why?
| | Fluoresceins | 1 | 2002 | 9 | 0.010 |
Why?
| | Microvilli | 1 | 2002 | 6 | 0.010 |
Why?
| | Delayed-Action Preparations | 1 | 2002 | 55 | 0.010 |
Why?
| | Dextrans | 1 | 2002 | 16 | 0.010 |
Why?
| | Drug Implants | 1 | 2002 | 35 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 126 | 0.010 |
Why?
| | Systole | 1 | 2002 | 73 | 0.010 |
Why?
| | Reference Values | 1 | 2002 | 313 | 0.010 |
Why?
| | Antibodies | 1 | 2002 | 152 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 404 | 0.010 |
Why?
| | Diet | 1 | 2003 | 588 | 0.010 |
Why?
|
|
Imig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|